Treatment of antiphospholipid syndrome beyond anticoagulation

Chrisanna Dobrowolski, Doruk Erkan

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the present time, treatment is primarily focused on anticoagulation. However, there is increasing awareness of the mechanisms involved in APS pathogenesis, which has led to the trial of novel therapies targeting those mechanisms. Following a brief review of the etiopathogenesis of and current management strategies in APS, this paper focuses on the evidence for these potential, targeted APS treatments, e.g., hydroxychloroquine, statins, rituximab, belimumab, eculizumab, defibrotide, sirolimus, and peptide therapy.

Original languageEnglish (US)
Pages (from-to)53-62
Number of pages10
JournalClinical Immunology
StatePublished - Sep 2019
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Treatment of antiphospholipid syndrome beyond anticoagulation'. Together they form a unique fingerprint.

Cite this